Edition:
United States

Otsuka Holdings Co Ltd (4578.T)

4578.T on Tokyo Stock Exchange

5,188JPY
23 Apr 2018
Change (% chg)

¥-114 (-2.15%)
Prev Close
¥5,302
Open
¥5,257
Day's High
¥5,261
Day's Low
¥5,172
Volume
1,047,900
Avg. Vol
1,126,658
52-wk High
¥5,568
52-wk Low
¥4,290

Select another date:

Tue, Dec 19 2017

BRIEF-Otsuka Pharmaceutical Says Co, X-Chem Have Signed Collaborative Research Agreement To Advance Discovery Process For New Otsuka Drug Compounds

* OTSUKA PHARMACEUTICAL SAYS CO, X-CHEM INC HAVE SIGNED COLLABORATIVE RESEARCH AGREEMENT TO ADVANCE DISCOVERY PROCESS FOR NEW OTSUKA DRUG COMPOUNDS Source text for Eikon: Further company coverage:

BRIEF-Otsuka Holdings to transfer medical device business to unit

* Says co plans to transfer medical device business to co's wholly owned unit Otsuka Medical Devices Co Ltd, with effective date of Jan. 1, 2018

BRIEF-FDA accepts Otsuka's resubmission to support a regulatory review of Tolvaptan in the treatment of ADPKD

* FDA accepts Otsuka's resubmission to support a regulatory review of Tolvaptan in the treatment of ADPKD

BRIEF-Otsuka Canada Pharmaceutical says Health Canada approves Otsuka and Lundbeck's Abilify Maintena as treatment for bipolar I disorder in adults​

* Otsuka Canada Pharmaceutical Inc-Health Canada approves Otsuka and Lundbeck's Abilify Maintena as treatment for bipolar I disorder in adults​ Source text for Eikon: Further company coverage:

BRIEF-Otsuka Holdings unit and Lundbeck to initiate third Phase 3 trial to evaluate brexpiprazole in treatment of agitation in patients with dementia of Alzheimer's type

* Says co's unit Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S will initiate a third clinical phase 3 study for brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type, in the first half of 2018

Select another date: